People · Operator
Named in public records as an officer, director or promoter · active 2010–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lycia Therapeutics, Inc. | — | Biotechnology | Series D+ | $202.0M | $1.2B | 2021 |
| Adverum Biotechnologies, Inc. | — | Biotechnology | Series D+ | $198.6M | $1.6B | 2024 |
| Lycia Therapeutics, Inc. | Director | Biotechnology | Series C | $75.0M | $314.3M | 2026 |
| Tobira Therapeutics, Inc. | — | Biotechnology | Series A | $23.2M | $513.3M | 2010 |
Laurent Fischer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Laurent Fischer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Clare Ozawa | 2 | 8 |
| William Rieflin | 2 | 4 |
| Ming Fang | 2 | 4 |
| TIM ANDERSON | 2 | 3 |
| Aetna Wun Trombley | 2 | 3 |
| Patrick Heron | 1 | 11 |
| Brian Halak | 1 | 10 |
| Thomas Woiwode | 1 | 7 |
| James Sapirstein | 1 | 7 |
| Steven Schwartz | 1 | 6 |
| Daniel Turner | 1 | 4 |
| John McLaughlin | 1 | 3 |
| Eckard Weber | 1 | 3 |
| Carol Brosgart | 1 | 3 |
| Patrick Machado | 1 | 3 |
| Mark Blumenkranz | 1 | 3 |
| Thomas Chalberg | 1 | 2 |
| Paul Wachter | 1 | 2 |
| Mark S. Blumenkranz | 1 | 2 |
| Hans Hull | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.